1. Home
  2. PROK vs CCII Comparison

PROK vs CCII Comparison

Compare PROK & CCII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PROK
  • CCII
  • Stock Information
  • Founded
  • PROK 2015
  • CCII 2024
  • Country
  • PROK United States
  • CCII United States
  • Employees
  • PROK N/A
  • CCII N/A
  • Industry
  • PROK Biotechnology: Biological Products (No Diagnostic Substances)
  • CCII
  • Sector
  • PROK Health Care
  • CCII
  • Exchange
  • PROK Nasdaq
  • CCII Nasdaq
  • Market Cap
  • PROK 417.1M
  • CCII 350.7M
  • IPO Year
  • PROK N/A
  • CCII 2025
  • Fundamental
  • Price
  • PROK $2.97
  • CCII $10.30
  • Analyst Decision
  • PROK Strong Buy
  • CCII
  • Analyst Count
  • PROK 4
  • CCII 0
  • Target Price
  • PROK $6.25
  • CCII N/A
  • AVG Volume (30 Days)
  • PROK 2.1M
  • CCII 91.6K
  • Earning Date
  • PROK 11-11-2025
  • CCII 01-01-0001
  • Dividend Yield
  • PROK N/A
  • CCII N/A
  • EPS Growth
  • PROK N/A
  • CCII N/A
  • EPS
  • PROK N/A
  • CCII N/A
  • Revenue
  • PROK $527,000.00
  • CCII N/A
  • Revenue This Year
  • PROK $427.89
  • CCII N/A
  • Revenue Next Year
  • PROK N/A
  • CCII N/A
  • P/E Ratio
  • PROK N/A
  • CCII N/A
  • Revenue Growth
  • PROK N/A
  • CCII N/A
  • 52 Week Low
  • PROK $0.46
  • CCII $10.07
  • 52 Week High
  • PROK $7.13
  • CCII $10.35
  • Technical
  • Relative Strength Index (RSI)
  • PROK 55.05
  • CCII N/A
  • Support Level
  • PROK $2.80
  • CCII N/A
  • Resistance Level
  • PROK $3.28
  • CCII N/A
  • Average True Range (ATR)
  • PROK 0.27
  • CCII 0.00
  • MACD
  • PROK 0.01
  • CCII 0.00
  • Stochastic Oscillator
  • PROK 57.52
  • CCII 0.00

About PROK ProKidney Corp.

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

About CCII Cohen Circle Acquisition Corp. II Class A Ordinary Shares

Cohen Circle Acquisition Corp II is a blank check company.

Share on Social Networks: